• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Modus Therapeutics

0.37 SEK+3.06 %24.7, 17.25
Less than 1K followers

MODTX

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
+3.06 %
-1.86 %
-11.90 %
+17.09 %
+21.71 %
-24.92 %
-58.29 %
-81.81 %
-82.12 %

Modus Therapeutics operates in biotechnology. The product portfolio includes the drug candidate sevuparin. The company's focus is to develop sevuparin for patients with sepsis, septic shock and other conditions with systemic inflammation. In addition to its core business, it also offers service and related ancillary services. The business and related research are conducted with the largest presence in Sweden.

Read more
Market cap
55.02M SEK
Turnover
25.54K SEK
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
All
Press releases
3rd party
ShowingAll content types

Financial calendar
26.8
2026

Interim report Q2'26

24.11
2026

Interim report Q3'26

24.2
2027

Annual report '26

Regulatory press release18.06.2026, 18.10

Modus Therapeutics: SEVUSMART manuscript made available online ahead of peer review in Nature Communications

Modus Therapeutics
Press release16.06.2026, 11.15

Modus Therapeutics reports on preclinical data on sevuparin in CKD with anemia presented at EHA2026

Modus Therapeutics
Regulatory press release28.05.2026, 12.30

Annual General Meeting in Modus Therapeutics Holding AB (publ)

Modus Therapeutics

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press release26.05.2026, 08.00

Modus Therapeutics publishes interim report for Q1 2026

Modus Therapeutics
Press release21.05.2026, 14.30

Modus Therapeutics to present sevuparin data at the European Iron Club Meeting 2026 in Dublin

Modus Therapeutics
Press release13.05.2026, 10.15

Modus Therapeutics to present preclinical data on sevuparin in CKD with anemia at EHA2026 in Stockholm

Modus Therapeutics
Regulatory press release27.04.2026, 22.15

Modus announces outcome of exercise of warrants of series TO 2026 and receives approximately SEK 9.5 million

Modus Therapeutics
Regulatory press release27.04.2026, 14.00

Notice to Annual General Meeting in Modus Therapeutics Holding

Modus Therapeutics
Regulatory press release15.04.2026, 08.00

Modus Therapeutics Holding AB (publ) publishes annual report for the financial year 2025

Modus Therapeutics
Regulatory press release14.04.2026, 16.00

KDventures AB subscribes for all of its warrants of series 2025/2026 in Modus Therapeutics

Modus Therapeutics
Regulatory press release13.04.2026, 13.45

Correction of Previously Communicated Press Release

Modus Therapeutics
Regulatory press release13.04.2026, 08.00

Today the Exercise Period Begins for Modus Therapeutics Warrants Series 2025/2026

Modus Therapeutics
Regulatory press release25.02.2026, 08.00

Modus Therapeutics publishes year-end report for 2025

Modus Therapeutics
Press release10.12.2025, 13.00

First Patient Dosed in Part 2 of Modus Therapeutics’ Phase IIa Study in Chronic Kidney Disease with Anemia

Modus Therapeutics
Press release10.12.2025, 10.57

DNB Carnegie Access: Modus Therapeutics Holding: Discontinuing coverage

Modus Therapeutics
Press release28.11.2025, 15.00

DNB Carnegie Access: Modus Therapeutics Holding: Funding for next step secured – Q3 review

Modus Therapeutics
Regulatory press release26.11.2025, 08.00

Modus Therapeutics publishes Interim report for the third quarter 2025

Modus Therapeutics
Press release03.11.2025, 13.00

Modus Therapeutics receives regulatory approval for Part 2 of the Phase IIa study in CKD-with anemia

Modus Therapeutics
Regulatory press release24.10.2025, 08.30

Change of Certified Adviser (CA) to Bergs Securities

Modus Therapeutics
Press release18.09.2025, 09.00

Modus Therapeutics data to be presented at the 32nd Symposium on Glycosaminoglycans – sevuparin in focus for CKD with anemia

Modus Therapeutics